Role of antibodies in transplant-associated cardiac allograft vasculopathy

Zeitschrift fur Kardiologie

Volumn 89, Issue SUPPL. 9, 2000, Pages 11-15

  Rose, M L ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Alloantibodies; Anti endothelial antibodies; Chronic rejection; Endothelial cells; Minor antigens

Indexed keywords

ALLOANTIBODY; HLA ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CARDIAC ALLOGRAFT VASCULOPATHY; CELL ACTIVATION; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; GRAFT REJECTION; HEART TRANSPLANTATION; MOUSE; NONHUMAN; VASCULAR DISEASE;

EID: 0034439655     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920070014     Document Type: Conference Paper

References (51)

1. Heart transplant coronary artery disease detected by coronary angiography; a multiinstitutional study of preoperative donor and recipient risk factors
2. Coronary venous intimal thickening in explanted cardiac allografts. Evidence demonstrating that transplant coronary artery disease is a manifestation of a diffuse allograft vasculopathy
3. Transplant coronary disease: Non-immunological risk factors
4. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients
5. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone
6. Acute rejection and coronary artery disease in long term survivors of heart transplantation
7. The relationship among donor-recipient HLA mismatches, rejection and death from coronary artery disease in cardiac transplant recipients
8. Lack of association between endomyocardial evidence of rejection in the first six months and the later development of transplant-related coronary artery disease
9. Graft atherosclerosis; effects of cellular rejection and human lymphocyte antigen
10. Antiendothelial antibodies and coronary artery disease after cardiac transplantation
11. Identification of antiendothelial antibodies associated with accelerated coronary artery disease after cardiac transplantation
12. The role of anti-HLA antibodies in heart transplantation
13. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease
14. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: Association with chronic rejection
15. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation
16. A new enzyme linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared to cyclosporine
17. Experimental graft arteriosclerosis. I. The Lewis-to-F-344 allograft model
18. Coronary atherosclerosis in transplanted mouse hearts. 1. Time course and immunogenetic and immunopathological considerations
19. Sustained anti-CD4/CD8 treatment blocks inflammatory activation and intimal thickening in mouse heart allografts
20. Reduced transplant arteriosclerosis in murine cardiac allografts placed in interferon-g knockout recipients
21. Coronary atherosclerosis transplanted mouse hearts. II. Importance of humoral immunity
22. Alloantibody and T cell mediated immunity in the pathogenesis of transplant arteriosclerosis. Lack of progression to sclerotic lesions in B cell deficient mice
23. Immunologic basis of transplant-associated arteriosclerosis
24. Intimal thickening develops without humoral immunity in a mouse aortic model allograft model of chronic vascular rejection
25. Antibody induced arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes
26. Contribution of donor specific antibodies to acute allograft rejection. Evidence from B cell deficient mice
27. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: A possible mechanism for transplant atherosclerosis
28. Ligation of ICAM-1 on endothelial cells leads to expression of VCAM-1 via a nuclear factor kappa B independent mechanism
29. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet derived growth factor from endothelial cells
30. Antibodies to endothelial cells and vascular dysfunction in progressive systemic sclerosis and mixed connective tissue diseases
31. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon
32. Role of antibody tovascular endothelial cells in hyperacute rejection in patients undergoing cardiac transplantation
33. IgG antiendothelial antibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro
34. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis
35. In vitro stimulation of human endothelial cells by sera from a subpopulation of high percentage panel reactive antibody patients
36. Endothelial cell activation by sera containing HLA antibodies is mediated by interleukin-1
37. Direct and indirect pathways of allorecognition; relevance to acute and chronic allograft rejection
38. Role of antibody and indirect antigen presentation in transplant-associated coronary artery vasculopathy
39. T cell requirements for the rejection of renal allografts bearing an isolated class I MHC disparity
40. Indirect T allorecognition and alloantibody mediated rejection of MHC class I disparate heart grafts
41. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts
42. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans
43. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction
44. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
45. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation
46. Association of pretransplantation antiheart antibodies with clinical course after heart transplantation
47. Anti-skeletal muscle glycolipid antibodies in human heart transplantation as predictors of acute rejection; comparison with other risk factors
48. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis; a basis for peptide-specific therapy after onset of clinical disease
49. Much ado about minor histocompatibility antigens
50. Murine orthotopic corneal transplantation in high risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens
51. Evidence that CD31, CD49b and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants